Citius Pharmaceuticals Inc
CTXR
查看详细走势图
0.680USD
-0.014-2.05%
交易中 （美东）报价延迟15分钟
20.40K总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.05%
5天
-11.76%
1月
-8.11%
6月
-42.37%
今年开始到现在
-12.48%
1年
-56.13%
查看详细走势图
TradingKey Citius Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Citius Pharmaceuticals Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名192/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.00。中期看，股价处于平稳状态。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Citius Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Citius Pharmaceuticals Inc亮点
亮点风险
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
分析师目标
根据
2
位分析师
买入
评级
5.000
目标均价
+620.25%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Citius Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Citius Pharmaceuticals Inc简介
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
公司代码CTXR
公司Citius Pharmaceuticals Inc
CEOMazur (Leonard L)
网址https://www.citiuspharma.com/
相关品种
